- Company
- Anemia drug ‘Vadanem’ makes 2nd attempt at reimb listing
- by Nho, Byung Chul Mar 8, 2024 05:18am
- Vadanem, Mitsubishi Tanabe Pharma’s new tablet anemia drug, will likely receive approval from the U.S. Food and Drug Administration by early April and make a second attempt at getting a reimbursement listing in Korea. If the company gets the drug reasonably priced comparable to a weighted average price of the substitute during drug pri
- Company
- Oral PNH drug Fabhalta to soon be released in Korea
- by Eo, Yun-Ho Mar 7, 2024 07:15am
- Novartis' new PNH drug Fabhalta is set to land in Korea. According to industry sources, Novartis Korea has submitted an application for the marketing authorization of its Paroxysmal Nocturnal Hemoglobinuria (PNH) drug Fabhalta (iptacopan) to the Ministry of Food and Drug Safety. Therefore, the drug is expected to be approved within this
- Company
- Rare drug Ultomiris posts KRW 40 billion in sales in 3 yrs
- by Nho, Byung Chul Mar 6, 2024 06:03am
- Becoming a KRW 40 billion blockbuster in just 3 years since its launch, the growth potential of AstraZeneca’s Ultomiris Inj (ravulizumab) is gaining industry-wide attention. The biological orphan drug Ultomiris Inj. is considered to be the successor to Soliris Inj. (eculizumab) with significant improvements in dosing convenience. T
- Company
- Reimb for Verzenio in early breast cancer undergoes review
- by Eo, Yun-Ho Mar 6, 2024 06:03am
- Verzenio, the first CDK4/6 inhibitor to apply for insurance reimbursement in early breast cancer, is taking the second step to extend its reimbursement coverage. According to a report, the agenda of reimbursing Lilly Korea’s Verzenio (abemaciclib) will be presented to the Health Insurance Review and Assessment Service's Cancer Disease De
- Company
- Cash cow ‘bepotastine’ to face reimb re-evaluation
- by Chon, Seung-Hyun Mar 6, 2024 06:02am
- In facing re-evaluation of ‘bepotastine’ for reimbursement in the upcoming year, pharmaceutical companies fear its impact. The market size for bepotastine has increased by more than 50% in just two years during the pandemic and endemic, labeling bepotastine as a new cash cow. However, there are concerns that the companies may face financial lo
- Company
- Dupixent, 1st biologic approved for pruritic rash indication
- by Son, Hyung-Min Mar 5, 2024 05:49am
- As Dupixent is approved to treat prurigo nodularis (nodular itchy rash), the drug emerged as the only available treatment option among biologic agents. Previously, there were limited treatment options for treating prurigo nodularis, a condition that causes extreme itchiness. Sanofi hosted a press conference at Novotel Ambassador Seoul
- Company
- Kolon Life Science appeals to the Supreme Court for Invossa
- by Nho, Byung Chul Mar 5, 2024 05:49am
- On the 28th, Kolon Life Sciences decided to appeal to the Supreme Court against the manufacturing and sales license revocation ruling that had been made for its knee osteoarthritis cell gene therapy Invossa-K Inj (“Invossa”). In its appeal to the court, Kolon Life Sciences explained, "While we respect the court's decision, we will str
- Company
- Hugel receives FDA approval for its botulinum toxin Letybo
- by Nho, Byung Chul Mar 5, 2024 05:48am
- On the 4th, Hugel, a global total medical aesthetics company, announced that the company has received marketing approval from the U.S. Food and Drug Administration (FDA) on February 29th for 50 units and 100 units of its botulinum toxin Letybo (Korean brand name: Botulax). The FDA approval of Letybo represents a strong affirmation of Hu
- Company
- New multiple myeloma Ab ‘Elrexfio’ expects to enter KOR
- by Eo, Yun-Ho Mar 5, 2024 05:48am
- ‘Elrexfio,’ a new bispecific antibody to treat multiple myeloma, is expected to become commercially available soon. Pfizer Korea has applied for approval of Elrexfio (elranatamab) last year, and it is currently under review by the Ministry of Food and Drug Safety (MFDS), according to industry sources. Elrexfio is expected to be comme
- Company
- Intensifying competition in ulcerative colitis drug market
- by Son, Hyung-Min Mar 4, 2024 05:53am
- New drug development for conquering ulcerative colitis drives competition among global pharmaceutical companies. Competition in the market will likely intensify due to the efficacy shown by new drugs, including JAK inhibitors Rinvoq and Xeljanz, anti-integrin drugs, and S1P receptor modulators, in clinical trials, in addition to biological medic
